Evidence map›Paper›PMID 38590144›Full record

ArticleJournal of medicinal chemistry2024

Pd

Tatiana J Carneiro, Ana L M Batista de Carvalho, Martin Vojtek, Raquel C Laginha, Maria Paula M Marques, Carmen Diniz, Ana M Gil

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medicinal chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Tatiana J CarneiroDepartment of Chemistry and CICECO - Aveiro Institute of Materials, University of Aveiro, 3810-193 Aveiro, Portugal.
Ana L M Batista de CarvalhoMolecular Physical-Chemistry R&D Unit, Department of Chemistry, University of Coimbra, 3004-535 Coimbra, Portugal.
Martin VojtekLAQV/REQUIMTE, Laboratory of Pharmacology, Department of Drug Sciences, Faculty of Pharmacy, University of Porto, 4150-755 Porto, Portugal.
Raquel C LaginhaMolecular Physical-Chemistry R&D Unit, Department of Chemistry, University of Coimbra, 3004-535 Coimbra, Portugal.
Maria Paula M MarquesMolecular Physical-Chemistry R&D Unit, Department of Chemistry, University of Coimbra, 3004-535 Coimbra, Portugal.ORCID 0000-0002-8391-0055
Carmen DinizLAQV/REQUIMTE, Laboratory of Pharmacology, Department of Drug Sciences, Faculty of Pharmacy, University of Porto, 4150-755 Porto, Portugal.
Ana M GilDepartment of Chemistry and CICECO - Aveiro Institute of Materials, University of Aveiro, 3810-193 Aveiro, Portugal.ORCID 0000-0003-3766-4364
Universidade do Porto · PTUniversity of Coimbra · PTUniversity of Aveiro · PT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cisplatin (cDDP) resistance is a matter of concern in triple-negative breast cancer therapeutics. We measured the metabolic response of cDDP-sensitive (S) and -resistant (R) MDA-MB-231 cells to Pd

Indexed as

Antineoplastic AgentsCisplatinDrug Resistance, NeoplasmTriple Negative Breast NeoplasmsCell Line, TumorFemaleHumansPalladiumSpermineAntineoplastic AgentsCisplatinPalladiumSpermine

Identifiers

PMID38590144
PMCPMC11056979
OpenAlexW4394619550

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.